Bayer Launches Phase 1 Clinical Trial for BAY3498264 to Target KRAS-Mutated Cancers
Bayer has officially begun a Phase 1 clinical trial for BAY3498264, an investigational oral selective SOS1 inhibitor designed to assess its safety, tolerability, and preliminary efficacy in patients with advanced KRAS G12C-mutated solid tumours.
This milestone marks a significant step in the fight against KRAS-driven cancers, particularly non-small cell lung cancer (NSCLC), pancreatic cancer, and colorectal cancer, which remain some of the most challenging malignancies to treat.
KRAS mutations are among the most common genetic alterations in cancer, playing a key role in tumour cell proliferation, survival, and growth through the mitogen-activated protein kinase (MAPK) signalling pathway.
BAY3498264, developed in-house by Bayer, targets this pathway by inhibiting SOS1, a crucial mediator of KRAS activation. By disrupting KRAS signalling, the compound has the potential to reduce or halt tumour progression, offering a promising new avenue for precision oncology.
The Global Head of Research and Early Development for Oncology at Bayer’s Pharmaceuticals Division emphasized the importance of this trial, stating that the start of this trial with their novel SOS1 small molecule inhibitor marks a significant step in their commitment to targeting key drivers of tumour cell survival and growth.
Furthermore, they added that this innovative approach has the potential to enhance treatment options available for patients, offering the possibility to reduce or potentially stop tumour progression.
The open-label, first-in-human dose escalation study (NCT06659341) will focus on determining the optimal dosage of BAY3498264 and assessing its safety profile. Importantly, the trial will explore the compound’s potential in combination therapy.
When paired with a KRAS-targeting agent, BAY3498264 is anticipated to enhance the inhibition of KRAS activity, further slowing or stopping cancer cell growth. This dual-therapy approach holds promise for improving treatment responses in cancers heavily reliant on the KRAS/MAPK pathway.
The urgency for such advancements is underscored by the alarming statistics surrounding lung cancer. As the leading cause of cancer-related deaths worldwide, lung cancer poses a significant global health challenge.
The International Agency for Research on Cancer projects a marked increase in both lung cancer incidence and mortality by 2040, highlighting the critical need for novel therapies that can address the high unmet medical demand.
Bayer’s latest initiative reflects a broader effort to tackle KRAS-mutated cancers, which have historically been resistant to conventional therapies. With the potential to treat a variety of malignancies, including NSCLC, pancreatic, and colorectal cancers, BAY3498264 represents a substantial advancement in Bayer’s precision oncology development portfolio.
The success of this Phase 1 trial could pave the way for improved outcomes in patients with KRAS-mutated tumours, providing new hope for those with limited treatment options. Bayer’s innovative approach to SOS1 inhibition underscores the company’s commitment to advancing cancer care and addressing some of oncology’s greatest challenges.
As BAY3498264 progresses through clinical development, it stands as a beacon of promise for the future of KRAS-targeted therapies – a step closer to transforming outcomes for patients battling advanced, treatment-resistant cancers.
News Credits: Bayer begins inhibitor study treating advanced KRAS-mutated tumours
Things you may also like: